Clinical Trials Logo

Malignant Melanoma, Metastatic clinical trials

View clinical trials related to Malignant Melanoma, Metastatic.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT01884961 Recruiting - Clinical trials for Metastatic Renal Cell Cancer

Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2

IL2HD
Start date: July 9, 2012
Phase: Phase 2
Study type: Interventional

Title: Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response Phase: Proof of Principle phase II study Study Design: Single center, open-label trial to assess the immune response and potential biomarkers predictive of response Study Duration: Total duration: 36 months Enrollment: 20 months Treatment: 5 months per patient Follow-up every three months Number of Subjects: Mini-max two-stage Simon design: • Step 1: 7 patients enrolled If tumor antigen-specific immune response is observed in at least 3 patients: • Step 2: recruitment of an additional 12 patients